Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 18 of 65 · 3101 articles
Trial design affects how quickly and reliably new IBD treatments are tested and approved, and can influence patient experience (placebo exposure, retention) and whether trial populations reflect real-world patients.
The study documents substantial increases in Crohn’s disease and ulcerative colitis prevalence and changing incidence patterns in Northeastern Italy from 2012–2024, which may affect healthcare demand and resource...
If lymphatic dysfunction helps cause or sustain Crohn’s inflammation, it could explain some classic disease features (patchy, transmural inflammation and mesenteric changes) and point to new treatment approaches aimed at...
Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar...
Automated, validated grading of UC on colonoscopy images could reduce variability between endoscopists and help standardize severity assessment that influences treatment planning.
A reproducible animal model of perianal fistulizing Crohn’s disease could help researchers study how fistulas form and persist and provide a test platform for new therapies before human trials.
Regulatory approvals and trial activity for upadacitinib (Rinvoq) affect availability and prescribing patterns for immunomodulatory treatment options used across autoimmune and inflammatory diseases, including IBD.
Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.
Researchers have found a short peptide in potato protein with antioxidant and anti-inflammatory properties and are testing it as a possible oral treatment for intestinal inflammation — a potential new, plant-derived...
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...
Obese patients with FibroScan-detected steatosis in this cohort had a high frequency of colitis and some cases of IBD, dysplasia, and cancer, which could affect screening and symptom evaluation decisions.
Based on the title and source metadata, this appears to be a clinical study related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from idp.nature.com.
FDA IND clearance lets PALI‑2108 move into a Phase 2 trial in Crohn’s disease, meaning the drug’s safety and efficacy will be formally tested in people with moderate-to-severe disease. The program is being run alongside...
Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from American journal of...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from International Journal...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and CRP. The original article is from Journal of medical biochemistry.
The study connects many IBD genetic risk regions to specific genes and cell types, helping prioritize drug targets. It also nominates a known small molecule (entrectinib) as a repurposing candidate via NLRP3/NEK7...
This study directly compares two rescue medications used when intravenous steroids fail in acute severe ulcerative colitis, reporting similar short-term remission and safety but a slower early response with tacrolimus —...
Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...
Preclinical data suggest blocking STAT3 with TTI-101 prevented colitis-associated colorectal tumors in a mouse model and altered tumor-related gene expression and the gut microbiome — findings that could guide future...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Frontiers in...
FDA clearance lets Palisade start a Phase 2 trial of PALI-2108 in moderate-to-severe Crohn’s disease, which could matter to patients and clinicians watching new oral treatments targeted to the lower intestine.
AI tools for endoscopic and multimodal IBD assessment could make scoring and monitoring more objective and consistent, which matters for treatment decisions and tracking remission or relapse. The review also flags...
Distinguishing Crohn’s disease from intestinal tuberculosis is a frequent problem in TB-endemic areas; a validated mobile ML tool could help clinicians make more accurate, faster diagnostic decisions and avoid...
Fibrotic strictures are a major cause of symptoms and surgery in Crohn’s disease; an oral anti‑fibrotic drug could offer a non‑surgical treatment option if trials show benefit and safety. This study tests RXC008...
A new oral investigational drug (TP317) is entering a Phase 1b study in adults with active UC to assess safety and pharmacokinetics, which may be relevant to patients seeking information about emerging therapies.
Microbial amino-acid metabolites may be active players in IBD biology and could become useful biomarkers or therapeutic targets. Understanding these metabolites helps explain links between the microbiome, immune...
This study describes a new nanoparticle (Ce‑TA) that reduced inflammation and tissue injury in a common mouse model of colitis, suggesting a possible future therapeutic avenue for IBD driven by antioxidant and...
A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.
Biologics can be critical for treating moderate-to-severe IBD, but cost and treatment failure limit access and long‑term use in this Indian cohort. Understanding uptake and reasons for stopping helps target interventions...
Patient engagement in treatment decisions can affect satisfaction, adherence, and care planning. This study identifies practical factors (treatment options, trusted providers, community support) associated with higher...
The study suggests quercetin can reduce inflammation and tissue damage markers in lab models of ulcerative colitis, pointing to ERK–MMP signaling as a possible mechanism. That could inform future preclinical research...
People diagnosed as IBDU want to know whether their disease course, treatment needs, and chance of later being reclassified differ from typical UC or Crohn's disease.
The study targets TLR2 activation by bacterial curli, a mechanism linked to inflammation in IBD and other immune conditions. Engineering curli to inhibit TLR2 could become a strategy to create probiotics that reduce...
A formulation that increases oral absorption of quercetin and reduces inflammation in animal models could point toward new flavonoid-based therapies for ulcerative colitis, but findings are preclinical.
Findings describe how often and when dysplasia recurs after ESD for UC-associated neoplasia, information that can affect decisions about endoscopic treatment versus colectomy and surveillance planning.
Identifies IL-1RN and SERPINA1 as biomarkers linked to macrophage-driven inflammation in ulcerative colitis and shows TolDCs can reduce macrophage pro-inflammatory cytokine expression in lab experiments — findings that...
The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when...
The study reports that kaempferol reduced inflammation, fibrosis, and barrier damage in mouse and cell models of colitis — mechanisms directly relevant to IBD progression and symptoms.
Predicting which children with Crohn disease will need surgery — and roughly when — could help families and clinicians plan treatments, monitoring, and discussions about elective bowel resection earlier in the disease...
A non-invasive MRI method that correlates with histology and endoscopic scores could reduce the need for frequent colonoscopy for assessing IBD activity and help monitor treatment response, especially when endoscopy is...
People with IBD may be concerned about environmental exposures that could influence inflammation or worsen disease. This review explains why micro- and nanoplastics are biologically plausible contributors but also why...
The study proposes a new immunomodulatory approach—phosphatidylserine liposomes—that reduced inflammation in mouse colitis models and altered monocyte and T-cell responses, which could point toward future therapies for...
If MSCs can limit ferroptosis via CBS, that points to a new biological pathway that might be targeted to reduce intestinal inflammation in Crohn's disease. This could guide future lab research and eventually early-phase...
The study evaluates whether microbial networks differ between groups (including sexes) in IBD and other diseases using a rigorously tested method; that matters because robust methods are needed before microbiome patterns...
The paper reframes Crohn’s disease and ulcerative colitis in terms of dominant T-helper immune pathways (TH1 vs TH22), which could steer research on targeted immunologic treatments and biomarkers.
